Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Gynecological Surgery

Fig. 1

From: HMG-CoA reductase inhibitor lovastatin upregulates plasminogen activator production through RhoA-signaling in peritoneal cell line Met5A

Fig. 1

Dose-dependency of lovastatin-stimulated tissue-type plasminogen activator (tPA) production. Met5A cells were treated with 0 (vehicle), 0.1, 0.3, or 1 µM lovastatin for 18 h. tPA protein content of cell lysate was measured by tPA enzyme-linked immunosorbent assay kit. Values are expressed as means optical density (450 nm) ± SD of three independent experiments performed in duplicate determination. *P < 0.05 versus control

Back to article page